Skip to main content

Investors

Ulisse Biomed Group is an integrated biotech group with proprietary technologies, developing diagnostic solutions with a focus on public health, distributed diagnostics and molecular innovation.

About Us

We are technology leaders in distribuited and connected diagnostics


Investors

The Ulysses Biomed Group is an integrated biotech group with proprietary technologies, developing diagnostic solutions with a focus on public health, distributed diagnostics and molecular innovation.


Information for shareholders

Main consultants

  • Euronext Growth Advisor
    BPER Banca S.p.A.
  • Specialist
    MIT SIM S.p.A.
  • Auditor
    Audirevi S.p.A.
  • Disclosure of Regulated Information
    la società si avvale del circuito eMarket-SDIR gestito da Spafid Connect S.p.A. con sede in Foro Buonaparte, 10 - 20121 Milano.

Identification Codes

The Ordinary Shares have been assigned the following identification codes:

  • Alphanumeric code: UBM
  • ISIN Code: IT0005451213


The Warrants have been assigned the following identification codes:

  • Alphanumeric code: WUBM26
  • ISIN Code: IT0005453789

Share capital and shareholders

The subscribed and paid-up share capital amounts to Euro 244,819.34 divided into 24,481,934 ordinary shares admitted to trading on Euronext Growth Milan (formerly AIM Italia) on 4 August 2021 without any indication of nominal value. The following table illustrates the relative composition of the shareholding structure:

Tabella Azionisti Responsive
Shareholder Number of Shares % share % voting rights
Stefano Lo Priore (**) (*) 3.717.968 15,19% 15,19%
Alberto Amati 2.672.537 10,92% 10,92%
Algebris Investments Limited 1.700.000 6,94% 6,94%
Good Harvest Ventures 1.549.154 6,33% 6,33%
Lorenzo Colombo (**) (***) 883.703 3,61% 3,61%
Copernico Innovazione S.r.l. (**) 826.597 3,38% 3,38%
Nicola Basile (****) 334.451 1,37% 1,37%
Bruna Marini (**) 231.438 0,95% 0,95%
Matteo Petti (**) 140.900 0,58% 0,58%
Altri azionisti soggetti a vincoli di lock-up 5.615.293 22,94% 22,94%
Mercato 6.809.893 27,82% 27,82%
Total 24.481.934 100,0% 100,0%

(*) Including 1,619,249 shares held directly and 2,098,719 shares held through Maximilian Holding LTD.

(**) Paciscente member of the Shareholders' Agreement signed on 21 December 2023.

(***) Of which 54,000 shares held directly and 829,703 shares held through Locorian s.s.

(****) Of which 54,000 shares held directly and 280,451 held through Bantess s.s.

Information Obligations of Significant Shareholders

Pursuant to the Euronext Growth Milan Rules, anyone holding at least 5% of a class of Ulisse BioMed S.p.A. shares is a "Significant Shareholder".

Reaching or exceeding the thresholds of 5%, 10%, 15%, 20%, 25%, 30%, 50%, 66.6% and 90%, as well as falling below these thresholds, constitutes a "Substantial Change" that must be communicated by the Significant Shareholders to the administrative body of Ulisse Biomed S.p.A.

To this end, the Significant Shareholder must notify Ulisse Biomed S.p.A. of the Substantial Change promptly and in any case within 4 trading days starting from the day on which he became aware of the transaction that could give rise to the obligation, regardless of the date of execution, or from the day on which the person subject to the obligation became aware of the events that lead to changes in the share capital, indicating
1. his or her identity; 2. the date on which Ulisse Biomed S.p.A. was informed; 3. the date on which the Substantial Change of Shareholding occurred; 4. the nature and extent of the Significant Shareholder's participation in the transaction. The notification must be made using the attached form, to be sent either by e-mail or by PEC to the following addresses respectively:


This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Relations Manager

Contact

Gabriele Salaris

  • Email
    This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Email
    This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Phone